Pharmacologic characterization of omidenepag isopropyl, a novel selective EP2 receptor agonist, as an ocular hypotensive agent

Kirihara T., Taniguchi T., Yamamura K., Iwamura R., Yoneda K., Odani-Kawabata N., Shimazaki A., Matsugi T., Shams N., Zhang J.-Z.

2018
Investigative Ophthalmology and Visual Science

View publication

Therapeutic Area

Glaucoma
Technology

Pharmacology

Affiliations

R & D Division, Santen Pharmaceutical Co., Ltd, Grand Front Osaka Tower A, Kita-Ku, Osaka, Japan; R & D Division, Santen Pharmaceutical Co., Ltd, Ikoma-shi, Nara, Japan; Corporate Research & Development, Ube Industries, Ltd, Ube, Yamaguchi, Japan; R & D Division, Santen Inc, Emeryville, CA, United States

Related Publications

Ab-Externo MicroShunt versus Trabeculectomy in Primary Open-Angle Glaucoma: 2-year Results from a Randomized, Multicenter Study

Panarelli JF, Moster MR, Garcia-Feijoo J, Flowers BE, Baker ND, Barnebey HS, Grover DS, Khatana AK, Lee B, Nguyen T, Stiles MC, Sadruddin O, Khaw PT.

Omidenepag Isopropyl in Latanoprost Low/Non-Responders with Primary Open-Angle Glaucoma or Ocular Hypertension: A Phase 3, Non-Randomized, Two-Phase, Open-Label Study

Panarelli JF, Bowden EC, Tepedino ME, Odani-Kawabata N, Pei Z, McLaurin EB, Ropo A.

The Development of a SIBS Shunt to Treat Glaucoma

Pinchuk L.

View all Glaucoma publications

Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022